Pediatric Psychopharmacology

When the first edition of Pediatric Psychopharmacology published in 2002, it filled a void in child and adolescent psychiatry and quickly establishing itself as the definitive text-reference in pediatric psychopharmacology. While numerous short, clinically focused paperbacks have been published since then, no competitors with the scholarly breadth, depth, and luster of this volume have emerged. In the second edition, Christopher Kratochvil, MD, a highly respected expert in pediatric psychopharmacology, joins the outstanding editorial team led by Dr. Martin and Dr. Scahill. In the new edition, the editors streamline the flow of information to reflect the growth in scientific data since the first edition appeared. The overall structure of the book remains the same, with major sections on underlying biology; somatic interventions; assessment and treatment; and special considerations.

Andrés Martin, MD, MPH is the Riva Ariella Ritvo Professor at the Yale Child Study Center. He serves as medical director of the Children's Psychiatric Inpatient Service (CIPS) at Yale-New Haven Children's Hospital, and as editor-in-chief of the flagship Journal of the American Academy of Child and Adolescent Psychiatry.
Lawrence Scahill, MSN, PhD is Professor of Nursing and Child Psychiatry at Yale University. He directs the Yale Research Unit on Pediatric Psychopharmacology focused on the development and testing of pharmacological treatments for children with serious psychiatric disorders.
Christopher J. Kratochvil, M.D. is the Assistant Vice Chancellor for Clinical Research at the University of Nebraska Medical Center. He serves as the Chief Medical Officer of UNeHealth. Additionally, he is a Professor of Psychiatry & Pediatrics, and Assistant Director of the Psychopharmacology Research Consortium.

Final Table of Contents:
Contributors xxi SECTION I BIOLOGICAL BASES OF PEDIATRIC PSYCHOPHARMACOLOGY I-A Developmental Principles of Neurobiology and Psychopharmacology 3 1. Overview of Brain Development 5 Flora M. Vaccarino and James F. Leckman 2. Synaptic Function and Biochemical Neuroanatomy 23 Stephan Heckers, Christine Konradi, and George M. Anderson 3. Developmental Principles of Pharmacokinetics 38 Alexander A. Vinks, Philip D. Walson, and Shannon N. Saldaña 4. Cytochrome P450-Mediated Interactions 50 Jessica Oesterheld and Miia Turpeinen I-B Genetic Principles 65 5. Molecular Genetics 67 Susan Goebel-Goody, Surojit Paul, and Paul J. Lombroso 6. Pharmacogenetics 81 George M. Anderson, Jeremy Veenstra-VanderWeele, Edwin H. Cook, and James T. McCracken I-C Developmental Psychopathology 93 7. Neurobiology of Attention Regulation and its Disorders 95 A.F.T. Arnsten and F.X. Castellanos 8. Neurobiology of Early Life Stress: Evolving Concepts 112 Joan Kaufman and Natalie Weder 9. Neurobiology of Early-Onset Mood Disorders 124 Frank P. MacMaster, David R. Rosenberg, and Joan Kaufman 10. Neurobiology of Early-Onset Anxiety Disorders 139 Kate B. Nooner, Amy K. Roy, and Daniel S. Pine 11. Neurobiology of Obsessive-Compulsive Disorder 148 Tanya K. Murphy, Kytja K.S. Voeller, and S. Evelyn Stewart 12. Neurobiologic Substrates of Tic Disorders 171 James F. Leckman, Michael H. Bloch, Michelle Hampson, and Robert A. King 13. Neurobiology of Childhood Schizophrenia and Related Disorders 189 Anand Mattai, Judith L. Rapoport, and Nitin Gogtay 00-Martin_FM.indd xvii 10/4/2010 12:54:10 PM OUP UNCORRECTED PROOF - REVISES, 04/10/2010, GLYPH xviii CONTENTS 14. Neurobiology of Autism Spectrum Disorders: Implications for Improving Pharmacotherapy 200 Alexander Westphal and Kevin Pelphrey 15. Neurobiology of Aggression 211 Markus J.P. Kruesi, Sondra Keller, and Julie Ann Jensen 16. Neurobiology of Eating Disorders 226 Johannes Hebebrand, Kerstin Konrad, and Beate Herpertz-Dahlmann 17. Neurobiology of Substance Abuse Disorders 237 Kathryn J. Reissner and Peter W. Kalivas
SECTION II SOMATIC INTERVENTIONS II-A Psychotropic Agents 249 18. Stimulants 251 J. Daughton and Christopher Kratochvil 19. á 2 -Adrenergic Agonists: Clonidine and Guanfacine 263 Jeffrey H. Newcorn, Suzanne Clerkin, Kurt P. Schulz, and Jeffrey M. Halperin 20. Antidepressants I: Selective Serotonin Reuptake Inhibitors 275 Paul E. Croarkin, Graham J. Emslie, and Taryn L. Mayes 21. Antidepressants II: Other Agents 296 Emily Frosch 22. Mood Stabilizers: Lithium, Anticonvulsants, and Others 297 Robert A. Kowatch, Jeffrey R. Strawn, and Arman Danielyan 23. Antipsychotic Agents: Traditional and Atypical 312 Christoph U. Correll 24. Anxiolytics and Sedative/Hypnotics: Benzodiazepines, Buspirone, and Others 338 Shannon R. Barnett and Mark A. Riddle II-B Other Somatic Interventions 351 25. Complementary and Alternative Medicine in Pediatric Psychopharmacology 353 Joseph M. Rey, Garry Walter, and Nerissa Soh 26. Electroconvulsive Therapy, Transcranial Magnetic Stimulation, and Vagus Nerve Stimulation 363 Garry Walter, Joseph M. Rey, Neera Ghaziuddin, and Colleen Loo
SECTION III ASSESSMENT AND TREATMENT III-A General Principles 377 27. Running a Pediatric Psychopharmacology Clinic: Practical Aspects 379 Carlo G. Carandang, Christopher J. Kratochvil, Lawrence Scahill, and Andrés Martin 28. Clinical Instruments and Scales in Pediatric Psychopharmacology 389 Elizabeth Hurt, L. Eugene Arnold, and Michael G. Aman 29. Combining Pharmacotherapy and Psychotherapy: An Evidence-based Approach 407 Christopher J. Kratochvil, Karen Wells, and John S. March 00-Martin_FM.indd xviii 10/4/2010 12:54:10 PM OUP UNCORRECTED PROOF - REVISES, 04/10/2010, GLYPH CONTENTS xix 30. Thinking About Prescribing: The Psychology of Psychopharmacology 422 Kyle D. Pruett, Shashank V. Joshi, and Andrés Martin III-B Specifi c Disorders and Syndromes 435 31. Assessment and Treatment of Attention Defi cit Hyperactivity Disorder 437 Thomas Spencer, Joseph Biederman, and Timothy Wilens 32. Assessment and Treatment of Child and Adolescent Depressive Disorders 453 Boris Birmaher and David Brent 33. Assessment and Treatment of Child and Adolescent Bipolar Disorder 466 Jayasree J. Nandagopal and Melissa P. DelBello 34. Assessment and Treatment of Child and Adolescent Anxiety Disorders 480 John Walkup 35. Assessment and Treatment of Obsessive Compulsive Disorder 496 Gagan Joshi and Daniel A. Geller 36. Assessment and Treatment of Tourette Syndrome and Other Tic Disorders 516 Lawrence Scahill, Robert A. King, Paul Lombroso, Denis G. Sukhodolsky, and James F. Leckman 37. Assessment and Treatment of Early-onset Schizophrenia Spectrum Disorders 531 Linmarie Sikich and Terrence Carter Bethea 38. Assessment and Treatment of Autistic and Other Pervasive Developmental Disorders 547 Christopher J. McDougle and David J. Posey 39. Assessment and Treatment of Post-traumatic Stress Disorder 561 Craig L. Donnelly and Jennifer L. Mclaren 40. Assessment and Treatment of Eating Disorders and Obesity 570 Beate Herpertz-Dahlmann and Johannes Hebebrand III-C Special Clinical Populations 585 41. Psychopharmacology and Substance Use Disorders 587 Martin Gignac, James G. Waxmonsky, and Timothy Wilens 42. Individuals with Intellectual Disability 600 Michael G. Aman, Cristan A. Farmer, Ronald L. Lindsay, and L. Eugene Arnold 43. Psychopharmacology in the Medically Ill Child or Adolescent 617 Jonathan A. Slater, John Saroyan, and Nika Dyakina 44. Psychopharmacology During Pregnancy: Infant Considerations 627 C. Neill Epperson 45. Psychopharmacological Treatment of Preschoolers 646 Mary Margaret Gleason 46. Insomnia in Children and Adolescents 657 Judith A. Owens 00-Martin_FM.indd xix 10/4/2010 12:54:10 PM OUP UNCORRECTED PROOF - REVISES, 04/10/2010, GLYPH xx CONTENTS III-D Other Areas of Clinical Concern 669 47. Aggression 671 Bruce Meltzer, Martha Castro, and Jean A. Frazier 48. Management of Elimination and Other Pelvic Disorders: Enuresis, Encopresis, and Psychopharmacological Effects on Sexual Function 682 William Reiner
SECTION IV EPIDEMIOLOGICAL, RESEARCH, AND METHODOLOGICAL CONSIDERATIONS 49. Pediatric Psychopharmacoepidemiology: Who Is Prescribing? And For Whom, How, and Why? 697 Peter S. Jensen 50. Clinical Trials Methodology and Design 711 Benedetto Vitiello and Lawrence Scahill 51. Regulatory Issues 725 Thomas P. Laughren and Mark A. Ritter 52. Ethical Issues in Pediatric Psychopharmacology 738 Mary Lynn Dell, Brigette S. Vaughan, and Christopher Kratochvil 53. Confl icts of Interest 752 Garry Walter, Joseph M. Rey, Christopher R. Thomas, and Andrés Martin 54. International Perspectives on Pediatric Medication for Emotional and Behavioral Disorders 763 Daniel J. Safer and Julie M. Zito
Appendix 775 Disclosures of Financial Interest 785 Index 791